医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

PhoreMost and inStem Enter Structural Biology Alliance

2019年07月08日 PM05:17
このエントリーをはてなブックマークに追加


 

CAMBRIDGE, England

PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has entered into a structural biology focussed collaboration with the Centre for Chemical Biology and Therapeutics (CCBT), Bangalore, India. CCBT at the Institute for Stem Cell Science and Regenerative Medicine (inStem) is funded by the Department of Biotechnology, Government of India,. The aim of the collaboration is the structural visualisation of novel druggable sites across multiple targets, to rapidly advance new therapies.

PhoreMost’s next-generation phenotypic screening platform SITESEEKER® probes the entire proteome in a live cell environment for novel druggable targets, enabling the systematic unmasking of cryptic druggable sites. PhoreMost has built a pipeline of novel targets and early drug discovery programmes using this platform, and the new collaboration will draw on CCBT’s structural and chemical biology expertise to progress selected targets within PhoreMost’s discovery portfolio.

CCBT is a state-of-the-art multidisciplinary effort, which was formed to pioneer innovative approaches to create chemical tools that modulate novel classes of targets. The Centre integrates biochemistry, genetics and cell biology with structural biology, computational chemistry and synthetic chemistry.

Dr Chris Torrance CEO of PhoreMost, said: “Since its inception, PhoreMost’s model has been to forge a new approach to drug discovery, working collaboratively with partners in order to progress new medicines. We are delighted to announce this alliance with the CCBT and inStem, which represents an important milestone for PhoreMost and has enormous potential to rapidly advance new therapies.”

Professor Apurva Sarin, Director, inStem said: “We are very pleased with the partnership forged between Phoremost and the CCBT under Prof. Ashok Venkitaraman’s leadership, and look forward to exciting outcomes from this effort.”

Professor Satyajit Mayor, Director, NCBS, and former Director, inStem, said:We are very excited to announce this collaboration with PhoreMost. The ability of PhoreMost’s SITESEEKER platform to identify first-in-class drug targets together with functional peptide ligands is highly complementary to the structural biology capabilities at inStem and the CCBT. We look forward to supporting drug discovery against these targets to progress the next generation of therapeutics.”

View source version on businesswire.com: https://www.businesswire.com/news/home/20190708005264/en/

CONTACT

Media enquiries

Zyme Communications

Katie Odgaard

E-mail: katie.odgaard@zymecommunications.com

Phone: +44 (0)7787 502 947

or

At PhoreMost Ltd

Dr Chris Torrance, CEO

E-mail: chris.torrance@phoremost.com

or

At inStem

Dr Anandi Karumbati

E-mail: anandisk@instem.res.in

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • GC Pharma Lights Up to Celebrate ‘World Hemophilia Day’
  • ノクソファームが敗血症性ショック治療の効用でビヨンダの特許を出願
  • 东阳光药选择ABEC大型发酵罐以提高生物制药生产能力
  • Aural Analytics, Inc. and Healint, Pte. Ltd. Partner on Integration of Speech Analytics into Healint’s Suite of Clinical Trials and Widely Used Consumer Applications
  • Anji Pharma Adds Clinical Sites to Accelerate Clinical Development of Pradigastat for the Treatment of Functional Constipation